Healthcare Intelligence
Ophthalmology & Vision Care
Real-time intelligence, expert analysis, and verified research for the Ophthalmology & Vision Care industry. Stay ahead in 3 minutes a day.
Stay ahead of Ophthalmology & Vision Care in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
AI diabetic retinopathy tool matches human reading centers in ONYX-1 study
Ocula360 AI platform showed 89% agreement with human graders in detecting DR severity across 120 ultra-widefield images.
Read full articleMemento Medicines raises $93M for dual-action retinal disease therapy
Biotech secures Series A funding for MMT-205, a bispecific antibody targeting both Tie2 activation and VEGF inhibition.
Read full articleMassage guns linked to severe retinal tears and vision loss risk
BMJ case report warns of retinal dialysis and tears after patient used percussive device on eyes for months.
Read full articleMerck's retinal drug advances as Memento enters crowded AMD market
Competition intensifies as Merck begins Phase 2b/3 trial while Memento plans 2027 clinical entry with similar approach.
Read full articleEylea HD extends dosing intervals up to 5 months for AMD patients
Updated US dosing allows selected patients to reach 5-month intervals after successful first year of treatment.
Read full articleForbion, RA Capital lead $93M round for Memento's retinal therapy
Investment includes Sanofi Ventures and Samsara BioCapital, with funds targeting IND-enabling studies for MMT-205.
Read full articleDoctors call for massage gun warnings after bilateral retinal injuries
Case report documents multiple tears and retinal dialysis from percussive device use, urging manufacturer guidelines.
Read full articleOcula360 AI platform trained on 487,000 images for DR screening
Web-based tool classifies diabetic retinopathy severity using ETDRS fields, showing potential for clinical trial recruitment.
Read full articleAI diabetic retinopathy tool matches human reading centers in ONYX-1 study
Ocula360 AI platform showed 89% agreement with human graders in detecting DR severity across 120 ultra-widefield images.
Read full articleMemento Medicines raises $93M for dual-action retinal disease therapy
Biotech secures Series A funding for MMT-205, a bispecific antibody targeting both Tie2 activation and VEGF inhibition.
Read full articleMassage guns linked to severe retinal tears and vision loss risk
BMJ case report warns of retinal dialysis and tears after patient used percussive device on eyes for months.
Read full articleMerck's retinal drug advances as Memento enters crowded AMD market
Competition intensifies as Merck begins Phase 2b/3 trial while Memento plans 2027 clinical entry with similar approach.
Read full articleEylea HD extends dosing intervals up to 5 months for AMD patients
Updated US dosing allows selected patients to reach 5-month intervals after successful first year of treatment.
Read full articleForbion, RA Capital lead $93M round for Memento's retinal therapy
Investment includes Sanofi Ventures and Samsara BioCapital, with funds targeting IND-enabling studies for MMT-205.
Read full articleDoctors call for massage gun warnings after bilateral retinal injuries
Case report documents multiple tears and retinal dialysis from percussive device use, urging manufacturer guidelines.
Read full articleOcula360 AI platform trained on 487,000 images for DR screening
Web-based tool classifies diabetic retinopathy severity using ETDRS fields, showing potential for clinical trial recruitment.
Read full articleStay ahead of Ophthalmology & Vision Care in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.